πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,589 results for β€œPharma” Clear

  1. KN046 （PD-L1/CTLA4 BsAbοΌ‰

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced HCC

    phase 2 small molecule terminated

    1 trial

  2. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  3. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Well-Controlled Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  4. KPL-404

    Kiniksa Pharmaceuticals International, plc

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  5. KPL-716

    Kiniksa Pharmaceuticals International, plc

    Chronic Idiopathic Urticaria

    phase 2 small molecule completed

    1 trial

  6. KPL-914

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule completed

    1 trial

  7. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  8. KVD824

    Kalvista Pharmaceuticals (Ireland) Limited

    Angioedema, Hereditary, Types I and II

    phase 2 small molecule terminated

    1 trial

  9. KVD900

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 2 small molecule completed

    2 trials

  10. LB-102

    LB PHARMACEUTICALS INC

    Bipolar I Disorder

    phase 2 small molecule active

    1 trial

  11. LB-208, LB-208

    AOP Orphan Pharmaceuticals GmbH

    Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

    phase 2 small molecule active

    1 trial

  12. LB101

    Centessa Pharmaceuticals plc

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  13. LB54640

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule completed

    1 trial

  14. LBR-101 High Dose

    Teva Pharma GmbH

    Episodic Migraine Headache

    phase 2 small molecule completed

    1 trial

  15. LBR-101 High Dose

    Teva Pharma GmbH

    Chronic Migraine

    phase 2 small molecule completed

    1 trial

  16. LCZ696

    Novartis Pharmaceuticals

    Hypertension

    phase 2 small molecule completed

    2 trials

  17. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  18. LEE011, LEE011, LTT462, LXH254, LXH254, TMT212, LXH254, LTT462, LXH254

    Novartis Pharmaceuticals

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

  19. LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB

    Novartis Pharmaceuticals

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  20. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  21. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≀ 5cm or - multiple tumours (max 3 lesions ≀ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: β€’ Serum AFP>100 ng/mL β€’ Infiltrative form β€’ Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  22. LEO 90105

    LEO Pharma A/S

    Psoriasis Vulgaris

    phase 2 small molecule completed

    1 trial

  23. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  24. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources